Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 95
Filter
1.
Clin Oral Investig ; 22(7): 2593-2597, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29450737

ABSTRACT

OBJECTIVES: To evaluate the correlation between dental plaque formation and gingival health in subjects performing high oral hygiene standards over short or extended intervals. MATERIALS AND METHODS: Fifty-two non-dental students volunteered for this study. The subjects, trained to perform high oral hygiene standards, were randomized to perform oral hygiene at 12-, 24-, 48-, or 72-h interval over 30 days. The plaque index (PlI) and the gingival index (GI) were evaluated at baseline, 15, and 30 days. For the statistical analysis, oral hygiene intervals were collapsed into daily (12 and 24 h; G12/24) and extended (48 and 72 h; G48/72) intervals. Summary statistics (mean ± SD) and Spearman correlations between the PlI and the GI at baseline, 15, and 30 days were estimated. RESULTS: At baseline, correlation coefficients between PlI and GI were positive for both groups (r = 0.29 and r = 0.25). At day 15 and 30, correlation was maintained with similar baseline values for the G48/72 group. GI levels did not increase despite an increase in PlI for the G12/24 group, and the correlation was lower than that observed at baseline (r = 0.13 vs. r = 0.29). CONCLUSIONS: In subjects with high oral hygiene standards, the oral hygiene frequency governs the correlation between dental plaque formation and gingival health. Subjects performing high oral hygiene standards at daily intervals will maintain gingival health in difference to subjects using extended hygiene intervals. CLINICAL RELEVANCE: Subjects performing high oral hygiene standards at daily intervals will maintain gingival health in difference to subjects using extended hygiene intervals.


Subject(s)
Dental Plaque/prevention & control , Gingivitis/prevention & control , Oral Hygiene/methods , Dental Plaque Index , Female , Humans , Male , Periodontal Index , Treatment Outcome , Young Adult
2.
J Periodontal Res ; 48(2): 243-51, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22970744

ABSTRACT

AIM: To determine the potential of recombinant human bone morphogenetic protein-2 (rhBMP-2) soak-loaded on to an absorbable collagen sponge (ACS) to induce local bone formation compared with the clinical reference demineralized bone matrix (DBM) and to investigate potential additive/synergistic effects of exogenous parathyroid hormone (PTH). METHODS: Critical-size (8 mm), through-through calvaria osteotomy defects in 160 adult male Sprague-Dawley rats were randomized to receive one of eight interventions: rhBMP-2/ACS, DBM, ACS, or serve as controls (empty defects) combined or not with systemic PTH. Ten animals from each group were followed for 4 and 8 wks for radiographic and histometric analysis. Multivariable analysis was used to assess the effect of experimental intervention and healing time on local bone formation. RESULTS: In the multivariable analysis, rhBMP-2/ACS exhibited significantly greater histologic bone formation than control (ß ± SE: 54.76 ± 5.85, p < 0.001) and ACS (ß ± SE: 9.14 ± 3.31, p = 0.007) whereas DBM showed significantly less bone formation than control (ß ± SE: -32.32 ± 8.23, p < 0.001). Overall, PTH did not show a significant effect on bone formation (ß ± SE: 2.72 ± 6.91, p = 0.70). No significant differences in histological defect closure were observed between 4 and 8 wks for all but the control group without PTH. CONCLUSION: rhBMP-2/ACS significantly stimulates local bone formation whereas bone formation appears significantly limited by DBM. Systemic application of PTH provided no discernible additive/synergistic effects on local bone formation.


Subject(s)
Bone Diseases/surgery , Bone Matrix/transplantation , Bone Morphogenetic Protein 2/therapeutic use , Parathyroid Hormone/therapeutic use , Skull/drug effects , Transforming Growth Factor beta/therapeutic use , Absorbable Implants , Animals , Bone Demineralization Technique , Bone Diseases/diagnostic imaging , Collagen , Craniotomy/methods , Drug Carriers , Drug Synergism , Humans , Male , Microscopy, Polarization , Osteogenesis/drug effects , Radiography , Random Allocation , Rats , Rats, Sprague-Dawley , Recombinant Proteins/therapeutic use , Skull/diagnostic imaging , Time Factors , Tissue Preservation/methods , Wound Healing/drug effects
3.
J Periodontal Res ; 47(5): 545-53, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22486242

ABSTRACT

BACKGROUND AND OBJECTIVE: A large body of evidence implies that growth and differentiation factors, based on their ability to regulate various functions of cells originating in the periodontal tissues, may support periodontal wound healing/regeneration, creating an environment conducive to and/or immediately inducing de novo tissue formation. This study presents a short systematic overview on growth and differentiation factor technologies evaluated in the clinic for their potential to enhance periodontal wound healing/regeneration. MATERIAL AND METHODS: Reports on growth and differentiation factor technologies evaluated in the clinic for their potential to enhance periodontal wound healing/regeneration were selected for review. RESULTS: Growth and differentiation factor technologies intended for periodontal wound healing/regeneration and evaluated clinically included platelet-derived growth factor, insulin-like growth factor-I and -II, basic fibroblast growth factor, bone morphogenetic protein-3 and growth differentiation factor-5; platelet-derived growth factor was the only Food and Drug Administration-approved commercially available growth and differentiation factor technology. In general, enhanced periodontal regeneration was observed in sites receiving growth and differentiation factors compared with control(s). However, improvements of relatively limited clinical magnitude have been shown thus far. CONCLUSION: Although growth and differentiation factors project considerable appeal as candidate technologies in support of periodontal wound healing/regeneration, current candidate and commercially available technologies enhance treatment outcomes only to a limited extent in clinical settings.


Subject(s)
Guided Tissue Regeneration, Periodontal/methods , Intercellular Signaling Peptides and Proteins/therapeutic use , Periodontal Diseases/therapy , Biomedical Technology , Humans , Platelet-Derived Growth Factor/therapeutic use , Regeneration/drug effects , Wound Healing/drug effects
4.
J Periodontal Res ; 47(2): 243-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22097911

ABSTRACT

BACKGROUND AND OBJECTIVE: Osteoactivin is a novel glycoprotein shown to exhibit an important role in regulating osteoblast differentiation and function. The aim of the present study was to evaluate the potential of osteoactivin to support bone regeneration using an established defect model. MATERIAL AND METHODS: Critical-size, 8-mm-diameter through-and-through calvarial osteotomy defects were created in 60 adult male Sprague-Dawley rats. Test animals received 0.1 mL of osteoactivin in phosphate-buffered saline (50 µg/mL) soak-loaded onto an absorbable collagen sponge. Controls received 0.1 mL of phosphate-buffered saline soak-loaded onto the absorbable collagen sponge or no further intervention (sham-surgery). The animals were euthanized 2 and 4 wk after treatment and histometric analyses were performed. RESULTS: The absorbable collagen sponge control (mean ± standard deviation: 40.9 ± 26.9%) showed borderline significant greater bone fill compared with sham-surgery (22.9 ± 15.8%; p = 0.10) and osteoactivin (20.2 ± 11.8%; p = 0.07) treatments at 2 wk. In contrast, osteoactivin (84.7 ± 15.8%) showed significantly greater bone fill than sham-surgery (28.4 ± 9.6%; p < 0.001) and absorbable collagen sponge (41.8 ± 22.1%; p < 0.001) at 4 wk. No animals receiving sham-surgery or absorbable collagen sponge exhibited complete bone fill at 4 wk while 70% of the animals receiving osteoactivin showed complete bone fill. CONCLUSION: Osteoactivin demonstrates a significant potential to support bone regeneration/formation. Studies using discriminating large animal models are necessary to explore clinical application for periodontal and craniofacial indications.


Subject(s)
Bone Diseases/drug therapy , Membrane Glycoproteins/therapeutic use , Osteogenesis/drug effects , Skull/drug effects , Animals , Bone Diseases/pathology , Bone Regeneration/drug effects , Craniotomy , Drug Carriers , Gelatin Sponge, Absorbable , Male , Random Allocation , Rats , Rats, Sprague-Dawley , Skull/pathology , Time Factors
5.
Orthod Craniofac Res ; 12(3): 263-70, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19627529

ABSTRACT

Surgical placement of endosseous oral implants is governed by the prosthetic design and by the morphology and quality of the alveolar bone. Nevertheless, often implant placement may be complexed, if at all possible, by alveolar ridge irregularities resulting from periodontal disease, and chronic and acute trauma. In consequence, implant positioning commonly necessitates bone augmentation procedures. One objective of our laboratory is to evaluate the biologic potential of bone morphogenetic proteins (BMP) and other candidate biologics, bone biomaterials, and devices for alveolar ridge augmentation and implant fixation using discriminating large animal models. This focused review illustrates the unique biologic potential, the clinical relevance and perspectives of recombinant human BMP-2 (rhBMP-2) using a variety of carrier technologies to induce local bone formation and implant osseointegration for inlay and onlay indications. Our studies demonstrate a clinically relevant potential of a purpose-designed titanium porous oxide implant surface as stand-alone technology to deliver rhBMP-2 for alveolar augmentation. In perspective, merits and shortcomings of current treatment protocol including bone biomaterials and guided bone regeneration are addressed and explained. We demonstrate that rhBMP-2 has unparalleled potential to augment alveolar bone, and support implant osseointegration and long-term functional loading. Inclusion of rhBMP-2 for alveolar augmentation and osseointegration will not only enhance predictability of existing clinical protocol but also radically change current treatment paradigms.


Subject(s)
Alveolar Ridge Augmentation/methods , Bone Morphogenetic Proteins/therapeutic use , Periodontal Diseases/surgery , Recombinant Proteins/therapeutic use , Transforming Growth Factor beta/therapeutic use , Animals , Biocompatible Materials/therapeutic use , Bone Morphogenetic Protein 2 , Bone Substitutes/therapeutic use , Dental Implantation, Endosseous/methods , Dental Implants , Dental Prosthesis Design , Disease Models, Animal , Drug Carriers , Guided Tissue Regeneration/methods , Humans , Osseointegration/drug effects , Osteogenesis/drug effects
6.
Orthod Craniofac Res ; 12(1): 20-4, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19154271

ABSTRACT

OBJECTIVES: To determine whether the tip of the interdental gingiva can serve as a visible guide for placement of mini-implants. SETTING AND SAMPLE POPULATION: Computer tomography (CT) images from 15 males and 15 females (mean age 27 years, range: 23-35 years) were used to evaluate the distance from the tip of the interdental gingiva to the alveolar crest from the central incisor to the 1st molar. The distance from a reference point to the tip of interdental gingiva was recorded from study models using a caliper. The distance between the reference point and the alveolar crest was recorded using CT and added to the model recordings thus providing the distance from the tip of interdental gingiva to the alveolar crest for the various interdental sites. Two-way anova and Student-Newman-Keuls test for multiple comparisons were used for the statistical analysis. RESULTS: There was no significant difference in the distance from the tip of interdental gingiva to the alveolar crest between maxilla and mandible. The distance between the tip of interdental gingiva and the alveolar crest at the central/lateral incisors was the shortest compared with that of other sites. There was also a statistically significant difference between the male and female groups except for the maxillary 2nd premolar/1st molar interradicular site. CONCLUSION: The tip of interdental gingiva appears a reasonable visual guide for the placement of mini-implants for orthodontic anchorage.


Subject(s)
Alveolar Process/anatomy & histology , Dental Implantation, Endosseous/methods , Gingiva/anatomy & histology , Orthodontic Anchorage Procedures/instrumentation , Adult , Alveolar Process/diagnostic imaging , Dental Implants , Female , Humans , Male , Miniaturization , Tomography, X-Ray Computed , Young Adult
7.
Int J Periodontics Restorative Dent ; 21(5): 461-73, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11693239

ABSTRACT

The objective of this study was to examine alveolar ridge augmentation following implantation of recombinant human bone morphogenetic protein (rhBMP-2) with an allogeneic freeze-dried demineralized bone matrix (DBM) mixed with autologous blood. A second objective was to evaluate bone-to-implant contact in induced bone. Bilateral surgically created supraalveolar ridge defects in five young adult beagle dogs were implanted with the rhBMP-2-DBM-blood device. Transmucosal dental implants were placed at weeks 8 and 16 postsurgery The animals were euthanized 24 weeks following ridge augmentation. Healing was uneventful in all animals. Radiographic observations indicated substantial bone formation, including regions of radiolucency, at week 8. At week 16, the radiolucencies were generally resolved, and the trabecular structure of the induced bone resembled that of the adjacent residual bone. There were no remarkable differences in radiographic observations between weeks 16 and 24 after ridge augmentation. Histologic analysis revealed dense woven and lamellar induced bone. Any residual DBM appeared remineralized, at least in part. A large portion of the dental implants (approximately 70%) were housed in induced bone with evidence of limited crestal resorption. There was no significant difference in bone density between induced and residual bone, and the levels of bone-to-implant contact were similar (approximately 55%). The rhBMP-2 construct used in this study has a potential to augment alveolar ridge defects. Also, no difference in levels of osseointegration may be expected in induced and residual bone following a two-stage procedure of rhBMP-2-induced ridge augmentation and dental implant placement.


Subject(s)
Alveolar Ridge Augmentation/methods , Bone Morphogenetic Proteins/therapeutic use , Bone Transplantation/pathology , Dental Implants , Osseointegration , Transforming Growth Factor beta/therapeutic use , Alveolar Process/diagnostic imaging , Alveolar Process/pathology , Animals , Bone Density , Bone Matrix/transplantation , Bone Morphogenetic Protein 2 , Bone Transplantation/diagnostic imaging , Bone Transplantation/methods , Connective Tissue/pathology , Dental Implantation, Endosseous , Dogs , Epithelium/pathology , Female , Follow-Up Studies , Humans , Mandible/diagnostic imaging , Mandible/pathology , Mandible/surgery , Osteogenesis/drug effects , Radiography , Recombinant Proteins , Statistics as Topic , Surface Properties , Transplantation, Homologous , Wound Healing
8.
J Periodontol ; 72(5): 651-8, 2001 May.
Article in English | MEDLINE | ID: mdl-11394401

ABSTRACT

BACKGROUND: Prosthetic-driven implant dentistry requires predictable procedures for alveolar ridge augmentation. The objective of this pilot study was to evaluate bone regeneration in mandibular, full-thickness, alveolar ridge, saddle-type defects following surgical implantation of recombinant human bone morphogenetic protein-2 (rhBMP-2) in a novel hyaluronan (HY) sponge carrier. This sponge was fabricated from auto-crosslinked HY. METHODS: Alveolar ridge defects (approximately 15 x 10 x 10 mm), 2 per jaw quadrant, were surgically prepared in each of 3 young adult American fox hounds. Four defects were immediately implanted with rhBMP-2/HY. Three defects were implanted with rhBMP-2 in an absorbable collagen sponge (ACS) carrier (positive control). The rhBMP-2 solution (1.5 ml at 0.2 mg/ml) was soak-loaded onto the HY and ACS sponges. Three defects were implanted with HY sponges soak-loaded with buffer without rhBMP-2 (negative control), while 2 defects served as surgical controls. The animals were euthanized at 12 weeks postsurgery for histometric analysis. RESULTS: Clinically, alveolar ridge defects receiving rhBMP-2/ACS exhibited a slight supracrestal expansion, while defects receiving rhBMP-2/HY were filled to contour. In contrast, the HY and surgical controls exhibited ridge collapse. rhBMP-2/HY-treated defects exhibited a dense bone quality without radiolucent regions observed in defects treated with rhBMP-2/ACS. The histometric analysis showed 100% bone fill for the rhBMP-2/ACS defects and 94%, 58%, and 65% bone fill for the rhBMP-2/HY, HY, and surgical control defects, respectively. CONCLUSIONS: The conclusions are based on data from 2 of 3 animals in the study. In one animal, no response to rhBMP-2 was observed with either carrier, and the animal may have been a non-responder of unknown nature. With this limitation, the observations herein suggest that: 1) HY supports significant bone induction by rhBMP-2; 2) the rhBMP-2-induced bone assumes qualities of the immediate resident bone; 3) HY alone exhibits no apparent osteoconductive potential; and 4) HY appears to resorb within a 12-week healing interval in the absence or presence of rhBMP-2. Thus, HY appears to be a suitable candidate carrier for rhBMP-2.


Subject(s)
Alveolar Bone Loss/drug therapy , Bone Morphogenetic Proteins/therapeutic use , Bone Regeneration/drug effects , Bone Substitutes/therapeutic use , Hyaluronic Acid/therapeutic use , Transforming Growth Factor beta/therapeutic use , Absorbable Implants , Alveolar Bone Loss/surgery , Alveolar Process/diagnostic imaging , Alveolar Process/pathology , Alveolar Ridge Augmentation , Animals , Bone Morphogenetic Protein 2 , Collagen/chemistry , Collagen/therapeutic use , Dogs , Drug Carriers , Humans , Hyaluronic Acid/chemistry , Osteogenesis/drug effects , Pilot Projects , Radiography , Recombinant Proteins
9.
J Bone Joint Surg Am ; 83-A Suppl 1(Pt 2): S136-45, 2001.
Article in English | MEDLINE | ID: mdl-11314791

ABSTRACT

BACKGROUND: The surgical placement of dental implants is governed primarily by the prosthetic design and secondarily by the morphology and quality of the alveolar bone. Implant placement may be difficult, if at all possible, due to alveolar ridge aberrations. In consequence, prosthetically dictated dental implant positioning often entails augmentation of the alveolar ridge and adjacent structures. The objective of this review is to discuss recent observations of the biologic potential, the clinical relevance, and the perspectives of the application of recombinant human bone morphogenetic protein-2 (rhBMP-2) technology for alveolar bone augmentation and dental implant fixation. METHODS: Our studies use discriminating, critical-size, supraalveolar defects in dogs to evaluate the biologic potential of the rhBMP-2 technology. We also use clinical modeling, including peri-implantitis and alveolar ridge defects and the maxillary sinus in preparation for clinical indications, in dogs and inhuman primates. RESULTS: The results suggest that rhBMP-2 has substantial potential to augment alveolar bone and support dental implant fixation and functional loading. CONCLUSION AND CLINICAL RELEVANCE: Inclusion of rhBMP-2 for alveolar bone augmentation and dental implant fixation will not only enhance the predictability of the existing clinical protocol but will also allow new approaches to these procedures.


Subject(s)
Alveolar Ridge Augmentation , Bone Morphogenetic Proteins/administration & dosage , Dental Implantation, Endosseous , Transforming Growth Factor beta , Alveolar Bone Loss/therapy , Animals , Bone Morphogenetic Protein 2 , Drug Carriers , Recombinant Proteins/administration & dosage
10.
J Periodontal Res ; 36(6): 341-54, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11762869

ABSTRACT

The last decade has seen an increasing number of clinical reports on guided tissue regeneration (GTR) for reconstruction of gingival recession defects. This article reviews the value of GTR in the management of gingival recession defects based on records from such reports. Studies and case-series using nonresorbable and bioresorbable membranes, studies comparing GTR to the subepithelial connective tissue graft (CTG) procedure, and histologic reports of healing following GTR, published in the English language from 1985 to 2000, were identified using a Medline search and were included in the data-base for this review. The Following pre- and post-treatment data were collated and evaluated for each of the reports: gingival recession depth, probing depth, clinical attachment level, and width of the keratinized gingiva. In perspective of the limitations of the studies reviewed, it has been shown that GTR may be used for reconstruction of gingival recession detects. Importantly it has not been shown that GTR provides an added clinical benefit for the patient treatment planned for reconstruction of gingival recession defects. i.e. GTR does not appear to offer a significant advantage over mucogingival procedures such as the connective tissue graft or the advanced flap procedure. It is imperative to recognize inherent technical difficulties associated with GTR including primary would closure and secondary membrane exposure: membrane exposures being negatively correlated to desired clinical outcomes. Also, membrane exposures appear consistently more common in smokers than in non-smokers. It is also imperative to recognize shortcomings and adverse effects including space maintenance and unacceptable foreign body reactions associated with some bioresorbable GTR technologies.


Subject(s)
Gingival Recession/surgery , Guided Tissue Regeneration, Periodontal , Absorbable Implants , Connective Tissue/transplantation , Gingiva/transplantation , Humans , Lactic Acid , Membranes, Artificial , Polyesters , Polymers , Smoking , Surgical Flaps
11.
J Clin Periodontol ; 27(9): 698-704, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10983604

ABSTRACT

BACKGROUND: Transforming growth factor-beta (TGF-beta) represents a family of growth-modulating proteins with fundamental roles in connective tissue and bone development. The objective of this study was to evaluate the potential for regeneration of alveolar bone and cementum following surgical implantation of recombinant human TGF-beta 1 (rhTGF-beta 1). METHOD: Bilateral, critical size, supra-alveolar periodontal defects in 5 beagle dogs were surgically implanted with rhTGF-beta 1 in a calcium carbonate carrier (CaCO3) or with carrier alone. The animals were euthanized at 4 weeks postsurgery and block-biopsies of the defects were processed for histologic and histometric analysis. RESULTS: Surgical implantation of rhTGF-beta 1 resulted in minimal, if any, stimulation of alveolar bone or cementum regeneration. Linear bone and cementum regeneration in rhTGF-beta 1-treated defects was 1.2+/-0.6 and 0.01+0.01 mm, respectively. Corresponding values for the controls were 1.0+/-0.6 and 0.01+/-0.03 mm. CONCLUSIONS: The results suggest that, under the conditions (dose, carrier, defect type) evaluated here, treatment of periodontal defects in beagle dogs with rhTGF-beta 1 may be of limited clinical benefit.


Subject(s)
Alveolar Process/drug effects , Bone Regeneration/drug effects , Dental Cementum/drug effects , Periodontal Diseases/drug therapy , Transforming Growth Factor beta/administration & dosage , Alveolar Process/pathology , Alveolar Process/physiopathology , Animals , Bone Regeneration/physiology , Dental Cementum/pathology , Dental Cementum/physiopathology , Disease Models, Animal , Dogs , Drug Evaluation, Preclinical , Drug Implants , Humans , Male , Periodontal Diseases/pathology , Periodontal Diseases/physiopathology , Recombinant Proteins/administration & dosage
12.
J Periodontol ; 71(7): 1139-43, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10960021

ABSTRACT

BACKGROUND: Preclinical studies have shown that the condition of the root surface may play a decisive role for outcome of wound healing between a mucogingival flap and a denuded root surface. Root surface demineralization has been shown to promote the establishment of a new connective tissue attachment. Conversely, root conditioning with extracellular matrix proteins or fluorides has produced outcomes characterized by a long junctional epithelium. Collectively, present evidence suggests that early events in the healing sequel; i.e., the adsorption and adhesion of blood elements to the root surface are critical for outcomes of wound healing between a mucogingival flap and a denuded root surface. Ultimately understanding and control of these events are vital for successful design and execution of periodontal regenerative protocols, particularly those involving root conditioning. Consequently, the objective of this study was to develop a screening model for immediate evaluation of the influence of root conditioning protocols on the adsorption and adhesion of blood to dentin surfaces. METHODS: Planed and citric acid-treated human dentin surfaces were exposed to fresh blood allowed to clot and were then rinsed before scanning electron microscopy evaluation. RESULTS: Citric acid treated planed dentin surfaces presented a thick network of fibrin directly attaching to the dentin surface entrapping cellular elements, mainly erythrocytes. In contrast, untreated, planed dentin exhibited an amorphous appearance with sparse strands of adsorbed fibrous proteins and few adherent erythrocytes. CONCLUSIONS: This in vitro screening model may effectively distinguish dentin surfaces with potential for enhanced adsorption and adhesion of blood elements. Periodontal regenerative protocols involving root conditioning unsuccessful in maintaining the experimentally imposed fibrin clot in this model may have lesser clinical significance than those that do.


Subject(s)
Drug Evaluation, Preclinical/methods , Models, Biological , Periodontal Ligament/physiology , Regeneration/drug effects , Tooth Root/drug effects , Alveolar Process/physiology , Blood Coagulation/drug effects , Cell Adhesion/drug effects , Citric Acid/pharmacology , Dentin/drug effects , Dentin/physiology , Humans , In Vitro Techniques , Microscopy, Electron, Scanning , Models, Dental , Regeneration/physiology , Root Planing , Surface Properties/drug effects
13.
J Periodontol ; 71(3): 433-7, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10776931

ABSTRACT

BACKGROUND: It is generally accepted that the primary cause of periodontitis is bacterial infection of long duration. In addition, there are several risk factors that may increase the probability and severity of periodontitis. For example, an increased breakdown of alveolar bone has been observed in smokers compared to never-smokers. The objective of this study was to investigate the association between cigarette smoking and periodontal health, in particular, furcation involvement in molar teeth. METHODS: One hundred twenty (120) adult regular dental patients, presenting with at least 20 teeth each, third molars excluded, were evaluated. Sixty of the subjects consumed an average (+/- SD) of 16.8 +/- 3.8 cigarettes daily and had smoked for 21.4 +/- 5.7 years. The remaining subjects presented a negative history of smoking. Periodontal conditions for the molar teeth were recorded at the first and second mandibular molar buccal furcation area. RESULTS: Oral hygiene standards and dental care habits did not differ notably between smokers and never-smokers. Smokers exhibited significantly fewer molar teeth than never-smokers (2.2 +/- 1.1 versus 3.0 +/- 0.8; P<0.01). Also, smokers exhibited significantly advanced gingival recession, probing depth, clinical attachment loss, furcation involvement, and tooth mobility compared to never-smokers (P<0.01). CONCLUSIONS: The results of this study suggest that long-term cigarette smoking significantly worsens periodontal health including degree and incidence of furcation involvement in molar teeth.


Subject(s)
Molar , Periodontal Diseases/etiology , Smoking/adverse effects , Adult , Alveolar Bone Loss/etiology , Chi-Square Distribution , Dental Care , Female , Furcation Defects/etiology , Gingival Recession/etiology , Humans , Incidence , Male , Mandible , Middle Aged , Oral Hygiene , Periodontal Attachment Loss/etiology , Periodontal Pocket/etiology , Periodontitis/etiology , Tooth Loss/etiology , Tooth Mobility/etiology
14.
J Periodontol ; 71(3): 488-96, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10776939

ABSTRACT

BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier induces bone for reconstruction of skeletal defects. The rhBMP-2/ACS implant is prepared by administering a rhBMP-2 solution to dry ACS. Once prepared, rhBMP-2/ACS forms a moldable, cohesive, and adhesive implant. However, rhBMP-2/ACS does not have sufficient structural strength to withstand soft tissue compression at specific anatomic sites. To more fully understand the mechanisms that affect bone induction by rhBMP-2/ACS in the presence of soft tissue compression, it would be useful to have a preclinical model that appropriately simulates such circumstances in patients. This pilot study evaluated one such potential model. METHODS: Bilateral, Class III alveolar defects were surgically produced in 4 adult mongrel dogs following extraction of the mandibular fourth premolars and reduction of the alveolar ridge. After an 8-week healing interval, mucoperiosteal flaps were elevated and rhBMP-2/ACS or rhBMP-2/ACS combined with hydroxyapatite (HA) was implanted into contralateral defects. The animals were euthanized at 12 weeks post-augmentation and block biopsies processed for histologic evaluation. RESULTS: Limited augmentation followed implantation of rhBMP-2/ACS (0.7 +/- 0.6 mm). In contrast, sites receiving rhBMP-2/ACS/HA exhibited clinically relevant ridge augmentation (5.5 +/- 1.6 mm). Defects implanted with rhBMP-2/ACS exhibited dense trabeculation within the corpus of the reduced alveolar process. The cortices appeared intact without evidence of expansion into the defect area. Three defects receiving rhBMP-2/ACS/HA exhibited sparse bone trabeculae amidst HA particles, fibrovascular tissue, and marrow. Commonly, the HA particles were encapsulated by fibrous tissue. Some particles were observed in contact with bone. CONCLUSIONS: The results suggests that rhBMP-2/ACS has limited effect alone in this augmentation model of Class III alveolar ridge defects. Inclusion of HA into the rhBMP-2 construct results in clinically relevant augmentation, however, the quality of bone is compromised.


Subject(s)
Absorbable Implants , Alveolar Ridge Augmentation/methods , Bone Morphogenetic Proteins/therapeutic use , Collagen , Mandible/surgery , Transforming Growth Factor beta/therapeutic use , Alveolar Process/pathology , Alveolectomy , Animals , Bicuspid/surgery , Biocompatible Materials/therapeutic use , Biopsy , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/administration & dosage , Bone Regeneration/drug effects , Bone Substitutes/therapeutic use , Disease Models, Animal , Dogs , Drug Carriers , Durapatite/therapeutic use , Humans , Mouth Mucosa/pathology , Pilot Projects , Pressure , Recombinant Proteins , Surgical Flaps , Tooth Extraction , Transforming Growth Factor beta/administration & dosage , Wound Healing
15.
Arch Oral Biol ; 44(8): 693-700, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10459781

ABSTRACT

Twenty, 5-week-old, male, Sprague-Dawley rats were divided into a control and a cyclosporin A (CSA) group for evaluating effects of the drug on condylar cartilage. Animals in the treatment group daily received CSA (15 mg/kg body wt) in mineral oil by gastric feeding over a 4-week observation interval. Control animals received mineral oil only. Five animals from each group were killed at weeks 2 and 4 of study. After histological processing, five tissue sections from the mid-region of the condyle were selected and examined. Three compositional zones (articular fibrous, proliferative, and hypertrophic) of the superior, posteriosuperior and posterior regions of the condylar cartilage were evaluated by light microscopy. At week 2, total condylar cartilage thickness was similar in the CSA and control groups, but the thickness of each zone was altered in CSA-treated animals, including a decrease of the fibrous and proliferative zones and an increase in hypertrophic zone compared to control (P<0.05). At week 4, CSA-treated animals exhibited overall decreased cartilage thickness, including decreased thickness of each zone compared to control (P<0.05). The results suggest that CSA has an inhibitory effect on the maturation of the mandibular condyle in rats.


Subject(s)
Cartilage, Articular/drug effects , Cyclosporine/pharmacology , Mandibular Condyle/drug effects , Animals , Cartilage, Articular/anatomy & histology , Cartilage, Articular/growth & development , Male , Mandibular Condyle/anatomy & histology , Rats , Rats, Sprague-Dawley
16.
J Clin Periodontol ; 26(6): 381-7, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10382578

ABSTRACT

This report describes observations of healing following guided tissue regeneration (GTR) including surgical implantation of the prostaglandin E1 analog misoprostol with calcium-layered methacrylate particles. Critical size, supra-alveolar periodontal defects were surgically created around the 3rd and 4th mandibular premolar teeth in 4 beagle dogs. Wound management included soaking with a 24 microg/ml misoprostol solution and implantation of the misoprostol/methacrylate composite. One jaw quadrant per animal was prepared for GTR using expanded polytetrafluoroethylene membranes. The gingival flaps were coronally advanced and sutured to submerge the teeth. The tissues covering the surgical sites daily received topical misoprostol in an oral adhesive over the 4-week healing interval. Upon euthanasia, tissue blocks were prepared for histometric analysis of regeneration of alveolar bone and cementum, root resorption and ankylosis. The defect area underneath the membrane and the density of methacrylate particles were recorded for the GTR defects. The methacrylate particles appeared encapsulated in a dense connective tissue without signs of an inflammatory reaction, some in contact to newly formed bone. Alveolar bone regeneration height averaged (+/-SD) 1.2+/-1.0 and 1.0+/-0.6 mm for GTR and non-GTR defects, respectively. Corresponding values for bone regeneration area were 1.3+/-1.0 and 0.7+/-0.5 mm2. Cementum regeneration was confined to the apical aspect of the defects. Small areas of root resorption and ankylosis were observed for all teeth. Bone regeneration area correlated positively to the defect area and negatively to the density of methacrylate particles in the GTR defects. The histologic observations suggest that the methacrylate composite has marginal potential to promote bone and cementum regeneration under provisions for GTR.


Subject(s)
Alveolar Bone Loss/surgery , Bone Regeneration/drug effects , Bone Substitutes , Guided Tissue Regeneration, Periodontal/methods , Implants, Experimental , Methylmethacrylates , Misoprostol/administration & dosage , Polyhydroxyethyl Methacrylate , Animals , Bone Substitutes/adverse effects , Dental Cementum/physiology , Dental Implantation, Endosseous , Dental Implants/adverse effects , Dogs , Guided Tissue Regeneration, Periodontal/adverse effects , Implants, Experimental/adverse effects , Male , Mandible , Methylmethacrylates/adverse effects , Polyhydroxyethyl Methacrylate/adverse effects , Regeneration/drug effects , Regression Analysis , Root Resorption/etiology , Tooth Ankylosis/etiology
17.
J Clin Periodontol ; 26(6): 392-400, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10382580

ABSTRACT

The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) concentration on regeneration of alveolar bone and cementum, and on associated root resorption and ankylosis. Contralateral, critical size, supra-alveolar, periodontal defects were surgically produced and immediately implanted with rhBMP-2 in an absorbable collagen sponge (ACS) carrier in 8, young adult, male, beagle dogs. 6 animals received rhBMP-2/ACS (rhBMP-2 at 0.05, 0.10, or 0.20 mg/mL; total construct volume/defect approximately 4.0 mL) in contralateral defects following an incomplete block design. 2 animals received rhBMP-2/ACS (rhBMP-2 at 0 and 0.10 mg/mL) in contralateral defects (controls). The animals were euthanised at 8 weeks post-surgery and block sections of the defects were collected for histologic and histometric analysis. Supra-alveolar periodontal defects receiving rhBMP-2 at 0.05, 0.10, or 0.20 mg/ml exhibited extensive alveolar regeneration comprising 86%, 96%, and 88% of the defect height, respectively. Cementum regeneration encompassed 8%, 6%, and 8% of the defect height, respectively. Root resorption was observed for all rhBMP-2 concentrations. Ankylosis was observed in almost all teeth receiving rhBMP-2. Control defects without rhBMP-2 exhibited limited, if any, evidence of alveolar bone and cementum regeneration, root resorption, or ankylosis. Within the selected rhBMP-2 concentration and observation interval, there appear to be no meaningful differences in regeneration of alveolar bone and cementum. There also appear to be no significant differences in the incidence and extent of root resorption and ankylosis, though there may be a positive correlation with rhBMP-2 concentration.


Subject(s)
Alveolar Bone Loss/drug therapy , Bone Morphogenetic Proteins/pharmacology , Bone Regeneration/drug effects , Dental Cementum/drug effects , Periodontal Attachment Loss/drug therapy , Regeneration/drug effects , Transforming Growth Factor beta , Absorbable Implants , Alveolar Bone Loss/surgery , Animals , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/adverse effects , Bone Morphogenetic Proteins/therapeutic use , Cattle , Collagen , Dental Implantation, Endosseous/methods , Dental Implants , Dogs , Humans , Implants, Experimental , Male , Mandible , Periodontal Attachment Loss/surgery , Recombinant Proteins/pharmacology , Root Resorption/etiology , Tooth Ankylosis/etiology
20.
J Periodontol ; 70(2): 189-94, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10102557

ABSTRACT

BACKGROUND: There have been several investigations on the role of cyclosporin A (CSA) in gingival hyperplasia in both animals and humans. However, less attention has been given to the drug's effect on alveolar bone. This study used light microscopy to histologically and histometrically evaluate the effects of CSA on alveolar bone in the rat. METHODS: Sixty, 6-week-old Sprague-Dawley rats were separated into test and control groups. Animals in the test group received CSA in mineral oil (30 mg/kg body weight) daily by gastric feeding over the 6-week study. Control animals received only mineral oil. Ten animals from each group were sacrificed at weeks 2, 4, and 6. After histologic processing, the labial crest of the alveolar bone in the anterior mandible was evaluated by light microscopy. RESULTS: A distinct pattern of increased osteoclasia and reduced bone formation was observed in the CSA-exposed animals compared to the controls. Increased osteoclasia was observed in periodontal sites and decreased bone formation was observed in symphyseal sites. CONCLUSIONS: The results suggest that CSA has distinct effects on alveolar bone.


Subject(s)
Alveolar Process/drug effects , Cyclosporine/pharmacology , Immunosuppressive Agents/pharmacology , Alveolar Bone Loss/chemically induced , Alveolar Bone Loss/pathology , Alveolar Process/pathology , Analysis of Variance , Animals , Bone Development/drug effects , Bone Matrix/drug effects , Bone Matrix/pathology , Cell Count/drug effects , Disease Models, Animal , Follow-Up Studies , Gingival Hyperplasia/chemically induced , Male , Mandible/drug effects , Mandible/pathology , Osteocytes/drug effects , Osteocytes/pathology , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...